ESMO 2016: Introduction to press briefs and presidential symposia
How can germline mutations distinguish risk for lethal and indolent prostate cancer?
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
Disparities in cancer risk management among BRCA carriers
Innovations in ovarian cancer treatment: PARP inhibitors